Egalet US INC.
Pharmaceutical company that develops and commercializes abuse-deterrent formulations.
Based in PA
AI Overview
With $200K in lobbying spend across 5 quarterly filings, Egalet US INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2018 to 2019.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Egalet US INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid
Advocated for access to abuse-deterrent formulations.
Advocated for access to abuse-deterrent formulations. Support for H.R. 5582 - Abuse Deterrent Access Act of 2018. Support for Sec. 6001 of H.R. 6 - SUPPORT for Patients and Communities Act.
Advocated for access to abuse-deterrent formulations. Support for Sec. 6012 of H.R. 6 - SUPPORT for Patients and Communities Act.
Support for H.R. 5582 - Abuse Deterrent Access Act of 2018.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.